Intravitreal Injection of Expansile Perfluoropropane (C3F8) for the Treatment of Vitreomacular Traction

Rodrigues, Ian; Stangos, Alexandros Athanasios; McHugh, Dominic; Jackson, Timothy L.

doi:10.1016/j.ajo.2012.08.018

Cited by 63 publications

(78 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was previously described that MHs with a diameter of <200 μm have a higher chance of closure after medical therapy, which cannot be confirmed by the study done at the Medical University of Graz. The MH, however, did show a width of 201 μm and a single case is of very low significance [4,5].…”

Section: Discussionmentioning

confidence: 99%

“…Release of VMT was successfully observed in 40% of patients within the first month and increased to 60% within half a year [4]. In 2016, Steinle et al assessed the posterior vitreous release rates after a single intravitreal injection of C3F8 for VMT treatment.…”

Section: Discussionmentioning

confidence: 99%

“…However, the second postulated predictive feature of a maximal foveal thickness less than 500 μm cannot be seen in the case series of the Medical University of Graz. Three patients (42.86%) had a maximal foveal thickness of more than 500 μm, among whom two had VMT release within 6 months [4].…”

Section: Discussionmentioning

confidence: 99%

“…Three studies, conducted by Rodrigues et al, Steinle et al, and Chan et al, investigating the release rate of VMT and MH closure using intravitreal perfluoropropane (C3F8) gas showed very promising results [4][5][6]. The purpose of the present case series was to further examine the effect of a single intravitreal C3F8 gas injection with patients showing symptomatic VMT with or without MH.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Haas

Mayer

Wackernagel

2017

Spektrum Augenheilkd.

View full text Add to dashboard Cite

SummaryBackground We aimed to assess the efficacy of a single intravitreal perfluoropropane (C3F8) gas injection for the treatment of vitreomacular traction with or without a macular hole. Methods In this retrospective case series, seven eyes of six patients with symptomatic vitreomacular traction documented on optical coherence tomography, one with a macular hole additionally, received a single intravitreal C3F8 gas injection of up to 0.3 ml. The primary endpoint was vitreomacular traction release at 1 month after injection. Secondary endpoints included resolution of vitreomacular adhesion within 6 months, nonsurgical closure of macular holes, and change in central foveal thickness and best-corrected visual acuity. Results Overall, on optical coherence tomography, six of seven eyes (85.7%) had release of vitreomacular traction during the entire study duration: three within 1 month of injection and the other three within 6 months. Of the latter group, two of the three eyes showed a concurrent epiretinal membrane and one concurrent diabetic retino-and maculopathy. The patient with a macular hole had resolution of vitreomacular traction within 1 month but had to undergo vitrectomy because of nonclosure of the macular hole. Associated adverse events were macular edema with a consequent lamellar hole after injection in one patient, and another patient developed retinal detachment. Conclusion Intravitreal C3F8gas injection is an inexpensive and promising minimally invasive option for the treatment of symptomatic and persistent vitreo-

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Haas

Mayer

Wackernagel

2017

Spektrum Augenheilkd.

View full text Add to dashboard Cite

show abstract

“…1 In some cases, however, persisting vitreomacular adhesion after partial PVD can lead to tractional macular alterations causing symptoms, including decreased visual acuity and metamorphopsia. 2,3 The tractional effects can lead to a number of clinical entities such as the vitreomacular traction (VMT) syndrome, idiopathic lamellar and full-thickness macular hole, maculoschisis, cystoid macular edema, and epiretinal membrane (ERM) formation. 4 Ocular coherence tomography (OCT) has provided a better understanding of the process of PVD and VMT, 1 resulting in a better classification of all stages of VMT.…”

Section: Introductionmentioning

confidence: 99%

Pneumatic release of focal vitreomacular traction

Claus

Feron

Veckeneer

2016

Eye

View full text Add to dashboard Cite

Ocriplasmin for symptomatic vitreomacular adhesion

Neffendorf¹,

Pringle²,

Jackson³

2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Symptomatic vitreomacular adhesion (sVMA) is a recognised cause of visual loss and by tradition has been managed by pars plana vitrectomy (PPV). A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of ocriplasmin. Objectives To assess the efficacy and safety of ocriplasmin compared to no treatment, sham or placebo for the treatment of sVMA.

show abstract

Intravitreal Injection of Expansile Perfluoropropane (C3F8) for the Treatment of Vitreomacular Traction

Cited by 63 publications

References 34 publications

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Effect of intravitreal C3F8 gas in patients with vitreomacular traction

Pneumatic release of focal vitreomacular traction

Ocriplasmin for symptomatic vitreomacular adhesion

Contact Info

Product

Resources

About